<DOC>
	<DOCNO>NCT00420355</DOCNO>
	<brief_summary>The objective study determine pharmacokinetics lopinavir , ritonavir , atazanavir lopinavir/ritonavir atazanavir use combination .</brief_summary>
	<brief_title>Pharmacokinetic Study Two HIV Protease Inhibitors Patients</brief_title>
	<detailed_description>Thirty patient HIV infection enrol open-label , parallel arm pharmacokinetic study . Subjects receive either lopinavir/ritonavir atazanavir/ritonavir part antiretroviral therapy pharmacokinetic study perform 12-20 day examine whether coadministration lopinavir atazanavir alters pharmacokinetics either agent . The safety agent combination also explore .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>HIVseropositive Currently receive atazanavir/ritonavir lopinavir/ritonavir combination 23 nucleoside RT inhibitor antiretroviral treatmentnaïve If female , childbearing potential childbearing potential agrees use barrier method contraception throughout study HIV1 RNA &gt; 400 copies/mL currently receive antiretroviral therapy Concurrent use CYP450 inhibitor inducer Concurrent use Pglycoprotein substrates , inhibitor , inducer Concurrent use medication know interact ritonavir atazanavir Presence chronic health condition deem investigator potentially impair lopinavir , ritonavir , atazanavir pharmacokinetics Presence conduction abnormality electrocardiogram Women pregnant breastfeed Laboratory Abnormalities baseline : Aminotransferases &gt; 3x ULN Serum bilirubin &gt; 5x ULN Serum creatinine &gt; 1.5x ULN Hemoglobin concentration &lt; 8.0 g/dL Absolute neutrophil count &lt; 800 cells/μL Platelet count &lt; 50,000 cells/μL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>antiretroviral therapy</keyword>
	<keyword>protease inhibitor</keyword>
	<keyword>drug interaction</keyword>
	<keyword>HIV infection</keyword>
	<keyword>acquire immunodeficiency syndrome</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>